Bone metastases are often seen in advanced malignant disease and are often symptomatic. It has been repeatedly proven that patients with advanced bone tumors or metastases have an accumulation of fractures, nerve complications or severe immobilizing pain. The bone-related events are limiting for patients especially in tumors like prostate cancer.
Radium-223 was approved in Switzerland in 2014 with the help of the University Hospital of Zurich. Ra-223 is an analog of calcium and lodges in active bone metastases. Due to the high and precise irradiation of radium-223, all bone metastases in the body are treated with a high local irradiation. Since radium-223 is a so-called alpha emitter, only about 10 cell diameters are treated locally. The indication is the treatment of patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases without known visceral metastases when chemotherapy is not indicated or in case of progression after docetaxel.
Patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases without known visceral metastases when chemotherapy is not indicated or in progression after docetaxel.
Laboratory Values: Hb < 10g/dl, Tc < 100,000 /ul, ANC < 1,500 ug/l
As a patient, you cannot register directly for a consultation. Please have your family doctor, specialist refer you. If you have any questions, please use our contact form.
Simply assign your patient via registration form.